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ABSTRACT: IMP dehydrogenase (IMPDH) catalyzes two very different chemical transformations, a
dehydrogenase reaction and a hydrolysis reaction. The enzyme toggles between the open conformation
required for the dehydrogenase reaction and the closed conformation of the hydrolase reaction by moving
a mobile ﬂap into the NAD site. Despite these multiple functional constraints, the residues of the ﬂap and
NAD site are highly diverged, and the equilibrium between open and closed conformations (Kc) varies
widely. In order to understand how differences in the dynamic properties of the ﬂap inﬂuence the catalytic
cycle, we have delineated the kinetic mechanism of IMPDH from the pathogenic protozoan parasite
Cryptosporidium parVum (CpIMPDH), which was obtained from a bacterial source through horizontal
gene transfer, and its host counterpart, human IMPDH type 2 (hIMPDH2). Interestingly, the intrinsic
binding energy of NAD+ differentially distributes across the dinucleotide binding sites of these two enzymes
as well as in the previously characterized IMPDH from Tritrichomonas foetus (TfIMPDH). Both the
dehydrogenase and hydrolase reactions display signiﬁcant differences in the host and parasite enzymes,
in keeping with the phylogenetic and structural divergence of their active sites. Despite large differences
in Kc, the catalytic power of both the dehydrogenase and hydrolase conformations are similar in CpIMPDH
and TfIMPDH. This observation suggests that the closure of the ﬂap simply sets the stage for catalysis
rather than plays a more active role in the chemical transformation. This work provides the essential
mechanistic framework for drug discovery.
Inosine-5′-monophosphate dehydrogenase (IMPDH)
1 cata-
lyzes the penultimate step in guanine nucleotide biosynthesis,
the NAD+-dependent conversion of inosine-5′-monophos-
phate (IMP) to xanthosine-5′-monophosphate (XMP). This
reaction controls the size of the guanine nucleotide pool,
which in turn controls proliferation (1). IMPDH inhibitors
are used as immunosuppressive, anticancer, and antiviral
agents (2, 3). Recently, IMPDH has emerged as an attractive
target for drugs against Cryptosporidium parVum, the intra-
cellular eukaryotic parasite that is a major cause of diarrhea
and malnutrition in the developing world and a serious
pathogen of AIDS and other immunosuppressed patients in
the industrialized world (4–6). The purine salvage pathway
of C. parVum relies solely on adenosine; guanine nucleotides
are produced by the consecutive actions of adenosine kinase,
AMP deaminase, IMPDH, and GMP synthase (7–9). CpIMP-
DH appears to have been obtained from epsilon proteobac-
teria via horizontal gene transfer and thus is highly diverged
from the human counterparts hIMPDH1 and hIMPDH2 (7,
10, 11). This situation contrasts with other Apicomplexan
parasites such as Plasmodium and Toxoplasma, which have
more complex purine salvage pathways and contain eukary-
otic IMPDHs similar to the human enzymes (12). Presum-
ably, the bacterial CpIMPDH confers an evolutionary
advantage uniquely suited to the metabolic demands of
Cryptosporidium.
The IMPDH reaction requires two different chemical
transformations, a redox step where Cys319 attacks IMP
producing NADH and the covalent intermediate E-XMP*
and a hydrolysis step that produces XMP (Figure 1; Tritri-
chomonas foetus IMPDH numbering) (13). When NADH
departs, a mobile ﬂap docks in the vacant dinucleotide site,
carrying the catalytic base, Arg418, into the active site. Thus
the ﬂap toggles the enzyme between dehydrogenase (ﬂap
open, dinucleotide site exposed) and hydrolase conformations
(ﬂap closed, dinucleotide site occluded). Compounds such
as mycophenolic acid inhibit IMPDH by competing with the
ﬂap for the vacant NAD+ site, thus trapping E-XMP* (Figure
1). Similarly, NAD+ inhibits by forming a nonproductive
E-XMP*·NAD+ complex.
Despite such multiple functional constraints, the residues
comprising the ﬂap and NAD+ site vary widely among
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Published on Web 07/22/2008enzymes from different sources, as does the equilibrium
between open and closed conformations (14–16). We have
proposed that this divergence is a response to naturally
occurring IMPDH inhibitors such as mycophenolic acid,
which traps E-XMP*, and mizoribine monophosphate, which
stabilizes the closed conformation. Indeed, a mutation that
causes resistance to mycophenolic acid renders the enzyme
hypersensitive to mizoribine, demonstrating how chemical
warfare at the microbial level might drive evolution (17).
IMPDHs that are resistant to mycophenolic acid have high
values of kcat, which indicates that the equilibrium between
open and closed conformations controls both inhibition and
the catalytic cycle (13). For efﬁcient catalysis, the afﬁnity
of the ﬂap and NAD+ must be balanced so that the productive
E·IMP·NAD+ complex can form but the nonproductive
E-XMP*·NAD+ complex does not accumulate. Together,
these observations pose an evolutionary conundrum: for
catalytic success, a mutation must simultaneously increase
(or simultaneously decrease) the afﬁnity of both the ﬂap and
NAD+.
CpIMPDH provides a convenient system to test these
ideas: while the active site of the hydrolase conformation of
CpIMPDH is very similar to that of the well-characterized
TfIMPDH (Figure 2), the equilibrium between open and
closed conformations varies dramatically (4 for CpIMPDH,
140 for TfIMPDH, and e0.2 in hIMPDH2; 16, 18).
Here we delineate the kinetic mechanism of CpIMPDH
and hIMPDH2 in order to investigate how differences in the
dynamic properties of the ﬂap inﬂuence the catalytic cycle
and to identify functional differences that might explain why
C. parVum discarded its eukaryotic IMPDH in favor of the
bacterial version. These experiments demonstrate that, despite
large differences in equilibrium between open and closed
conformations, the catalytic power of the hydrolase confor-
mation is similar among CpIMPDH and TfIMPDH. The
kinetic mechanism derived in this work has already proven
invaluable in inhibitor discovery (19).
MATERIALS AND METHODS
Materials. IMP, XMP, GMP, 3-acetylpyridine adenine
dinucleotide (APAD+), and NADH were purchased from
Sigma. NAD+ was purchased from Roche. DTT was
purchased from Research Organics, Inc. Tris, glycerol,
EDTA, trichloroacetic acid, and KCl were purchased from
Fisher Scientiﬁc. HA nitrocellulose ﬁlters were purchased
from Millipore. [8-14C]IMP was obtained from Moravek
Biochemicals, Inc. D2O and DCl were purchased from
Cambridge Isotope Laboratories, Inc. EICARMP was a gift
from A. Matsuda (Hokkaido University, Japan).
General. Free acid forms were used for all substrates,
products, and ligands with the following exceptions. The
sodium form of NADH was converted into a TrisH+ form
by cation exchange using Dowex 50WX4 resin (Sigma).
[8-14C]IMP was used as the ditriethylammonium salt.
Expression and Puriﬁcation of CpIMPDH. CpIMPDH was
expressed and puriﬁed as previously described (16). Purity
was >95% as assessed by SDS-PAGE. The concentration
of CpIMPDH was determined by Bio-Rad assay using IgG
as a standard and by active site titration with the irreversible
inactivator EICARMP (20) (data not shown). The Bio-Rad
assay overestimates enzyme concentration by a factor of 2.6.
This is comparable to the correction factors measured for
the IMPDHs from Escherichia coli (20) and T. foetus (18).
Steady-State Kinetics. Standard IMPDH assays were
performed in assay buffer (50 mM Tris-HCl, pH 8.0, 100
mM KCl, and 1 mM DTT) at 25 °C. The production of
NADH and reduced 3-acetylpyridine adenine dinucleotide
(APADH) was monitored spectrophotometrically at 340 nm
( ) 6.22 mM-1 cm-1) and 363 nm ( ) 9.1 mM-1 cm-1),
respectively. Steady-state parameters for the NAD+ reaction
were determined by measuring initial velocities while varying
bothsubstrates.InitialvelocitieswereﬁtbytheMichaelis-Menten
equation (eq 1) or an equation including uncompetitive
inhibition (eq 2) using SigmaPlot (Systat Software, Inc.)
V)Vm[S]/(KM+[S]) (1)
V)Vm/(1+(KM/[S])+([S]/Kii)) (2)
where V is the initial velocity, Vm is the maximal velocity,
KM is the Michaelis constant for substrate (S), and Kii is the
inhibition constant for S. Steady-state parameters with respect
to NAD+ were determined by deriving the apparent Vm values
from plots of initial velocity versus IMP concentration (eq
1). These were replotted versus NAD+ concentration, and
the steady-state parameters were calculated from eq 2.
Similarly, apparent Vm values from initial velocities versus
NAD+ concentration (eq 2) were replotted versus IMP
concentration, and the Michaelis constant for IMP was
derived from eq 1. The apparent steady-state parameters for
APAD+ were derived from initial velocity versus dinucle-
otide concentration at saturating IMP (500 µM) using eq 1.
Equilibrium Dissociation Constants (Kd). Ligand was
successively added to 0.1-0.15 µM CpIMPDH in assay
buffer at 25 °C. The equilibrium protein ﬂuorescence was
measured with a Hitachi F-2000 ﬂuorescence spectropho-
tometer. In order to minimize inner ﬁlter effects, excitation
FIGURE 1: The mechanism of the IMPDH reaction. (A) The chemical
transformations. (B) The protein conformational changes highlight-
ing the competition of the active site ﬂap and inhibitors such as
mycophenolic acid (MPA) for the dinucleotide site.
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for NAD+, XMP, and GMP were used. Emission was
monitored at 344 nm for IMP, NAD+, XMP, and GMP and
at 342 nm for NADH. Inner ﬁlter corrections were calculated
by the formula
Fc/Fo)antilog[(Aex+Aem)/2] (3)
where Fc is the corrected ﬂuorescence, Fo is the observed
ﬂuorescence, and Aex and Aem are the absorbencies at the
excitation and emission wavelengths, respectively. Fc/Fo was
less than 2 for all ligand concentrations used. Since purines
are known ﬂuorescent quenchers (21), nonspeciﬁc quenching
was measured by titrating ligand against a solution of L-Trp
and was described by the Stern-Volmer relation
F0/F)1+KQ[Q] (4)
where F0 is the unquenched ﬂuorescence, F is the ﬂuores-
cence at a given quencher (Q) concentration, and KQ is the
quenching constant. The experimentally determined values
of KQ with L-Trp were used to calculate correction factors
(F0/F) that were applied to the binding data. The values of
KQ
-1 for IMP, XMP, GMP, NAD+, and NADH are 5.5, 0.53,
1.1, 4.3, and 0.24 mM, respectively. The corrected ﬂuores-
cence due to binding (Fbind) was calculated using eq 5.
Fbind)Fo(Fc/Fo)(F0/F) (5)
The program DynaFit (22) was used to describe Fbind versus
ligand concentration with a simple one-step binding
mechanism.
SolVent Deuterium Isotope Effects. Assay buffer was
prepared in either H2Oo rD 2O. The pH meter readings for
the D2O solutions were adjusted by adding 0.4. Initial
velocities were measured for varying dinucleotide concentra-
tions in assay buffer with 500 and 400 µM IMP for
CpIMPDH and hIMPDH2, respectively. Steady-state pa-
rameters for the CpIMPDH reaction were derived from eq
2 and eq 1 for NAD+ and APAD+, respectively, and eq 2
was used for hIMPDH2.
Ligand Binding Kinetics. The kinetics of XMP binding
were measured with an Applied Photophysics SX.17MV
stopped-ﬂow spectrophotometer by monitoring the changes
in protein ﬂuorescence (excitation ) 295 nm, 320 nm cutoff
ﬁlter). Equal volumes of enzyme and XMP were combined
at time 0 in assay buffer at 25 °C giving a ﬁnal concentration
of 0.4 µM enzyme and 30 or 120 µM XMP.
Pre-Steady-State Kinetics. Pre-steady-state experiments
were performed monitoring either NADH absorbance (340
nm) or ﬂuorescence (340 nm excitation, 420 nm cutoff ﬁlter).
Enzyme and saturating IMP were preincubated and combined
with an equal volume of NAD+ at time 0. For CpIMPDH,
NAD+ was varied against a ﬁnal concentration of 500 µM
IMP and 2.7 and 1 µM enzyme for the absorbance and
ﬂuorescence experiments, respectively. Fluorescence experi-
ments with hIMPDH2 used ﬁnal concentrations of 20-200
µM NAD+ combined with 4.0 µM enzyme and 2 mM IMP.
Absorbance experiments also used 2 mM IMP but with 1,
1.75, or 3.5 µM enzyme with 400 µM NAD+ or 3.5 µM
enzyme with 1 mM NAD+.
Progress curves were ﬁt using either a single (eq 6) or




St is the signal at time t, A1 and A2 are the amplitudes of the
ﬁrst and second phases respectively, kobs1 and kobs2 are the
observed ﬁrst-order rate constants for the ﬁrst and second
phases respectively, V is the steady-state rate, and b is a
background term. The hyperbolic dependence of kobs on




FIGURE 2: The active site of IMPDH. (A) The open conformation from the X-ray crystal structure of E·IMP· -Me-TAD (PDB accession
number 1LRT) is shown in surface rendering while the ﬂap from the closed conformation is depicted in ribbon (PDB accession number
1PVN). Note how the ﬂap competes with  -Me-TAD. The active site is colored by conservation: magenta, conserved in all three enzymes;
tan, conserved in two enzymes; cyan, different in all three enzymes. The residues within4Åo fI M Pa n d -Me-TAD are listed using the
same color scheme. Figure is rendered in Chimera (49). (B) Selected alignments of CpIMPDH, TfIMPDH, and hIMPDH2 shown in the
Clustal X coloring scheme.
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concentration of [NAD+]a t1 / 2kmax.
Labeling IMPDH with [8-14C]IMP. Accumulation of the
covalent E-XMP* complex was measured from reactions
with 100 µM [8-14C]IMP, 500 µM NAD+, and 1 µM
CpIMPDH in assay buffer at 25 °C. Reactions were quenched
during the steady state prior to 10% completion by precipita-
tion with cold TCA to a ﬁnal concentration of 10%. Enzyme
was captured on 0.45 µm HA nitrocellulose ﬁlters (prewet
with 10% TCA) and washed with cold 10% TCA. Radio-
activity was measured by scintillation counting. Control
reactions lacked either enzyme or NAD+.
RESULTS
Steady-State Kinetic Parameters of CpIMPDH. We de-
termined the steady-state parameters for CpIMPDH using
active site titrated enzyme and varying both substrate
concentrations (Table 1). These values are in good agreement
with our previous report (16). Importantly, the values of kcat
for NAD+ and APAD+ are comparable, suggesting that these
two reactions share a common rate-limiting step, most likely
the hydrolysis of E-XMP*. Solvent isotope effects on kcat
of 2.6 and 3.3 were observed for the NAD+ and APAD+
reactions, respectively (Table 1), which further indicates that
the hydrolysis of E-XMP* is rate-limiting.
Ligand Binding to CpIMPDH. We measured the binding
of substrates and products to CpIMPDH by monitoring
changes in intrinsic protein ﬂuorescence. CpIMPDH contains
two Trp residues (Trp90 and Trp368). The corresponding
residues in TfIMPDH (Phe99 and Gln470, respectively) are
located ∼25 Å from the active site. Nevertheless, all ligands
produce decreases in CpIMPDH ﬂuorescence. Corrections
for inner ﬁlter effects and nonspeciﬁc quenching were made
as described in Materials and Methods. In all cases, the data
are well described by a simple binding mechanism. The
values of Kd for IMP, XMP, and GMP are similar (∼5 µM,
Table 2, Figure S1; the notation “S” denotes ﬁgures, etc., in
the Supporting Information). In contrast, NADH binds with
greater afﬁnity than NAD+ by a factor of 6 (Table 2). The
values of Kd for both IMP and NAD+ are signiﬁcantly lower
than their respective KM values. This observation suggests
that both substrates are “sticky”, i.e., react to form products
faster than they are released from the enzyme.
We also investigated the kinetics of XMP association and
dissociation. Despite the fact that XMP quenches the intrinsic
ﬂuorescence of CpIMPDH, we were unable to observe a
signal in the stopped-ﬂow spectroscopy experiments. We
conclude that the binding of XMP is too fast to measure
(g200 s-1).
The Pre-Steady-State Reaction of CpIMPDH. A pre-
steady-state burst of NADH production is observed when
the CpIMPDH reaction is monitored by absorbance (Figure
3A). The progress curve is well described by a single
exponential phase followed by a linear steady state (Figure
S2A). The value of kobs for the burst phase displays a
hyperbolic dependence on NAD+ concentration (Figure S2B,
Table 3). Since absorbance monitors both free and enzyme-
bound NADH (23), the maximum value of kobs (kburst ) 41
( 2s -1) is a composite rate constant including both hydride
transfer and NADH release. Therefore, 41 s-1 serves as a
lower limit for the rate of hydride transfer.
Fortuitously, purines are strong quenchers so that the
ﬂuorescence of NADH is quenched in the E-XMP*·NADH
complex and is only observed when NADH is released from
the enzyme (23). A burst of NADH production is also
observed when the CpIMPDH reaction is monitored by
ﬂuorescence, and again the progress curve is well described
by a single exponential burst phase followed by a linear
steady state (Figures 3B and S3A). The value of kobs is
hyperbolically dependent on NAD+ concentration with a
maximum value of 16 s-1 (Figure S3B, Table 3).
Accumulation of E-XMP* in the CpIMPDH Reaction. The
above experiments indicate that hydride transfer is fast and
hydrolysis is rate-limiting in the CpIMPDH reaction, which
predicts that E-XMP* will accumulate in the steady state.
Therefore, we measured the incorporation of radioactivity
into the protein during the reaction with [8-14C]IMP and
NAD+ (500 µM). This NAD+ concentration was chosen to
avoid formation of the nonproductive E-XMP*·NAD+
complex. No radioactivity is incorporated into protein if
NAD+ is omitted from the reaction. Under these conditions,
25 ( 3% of the enzyme is trapped as E-XMP*, which is
comparable to the burst amplitude of NADH produced at
similar NAD+ concentrations (30 and 21% at 600 and 300
µM NAD+, respectively).
Global Fits of the CpIMPDH Reaction. Values for the
individual rate constants in the kinetic mechanism of
CpIMPDH were derived by ﬁtting the absorbance and
ﬂuorescence stopped-ﬂow progress curves using the program
DynaFit (22) as described in the Supporting Information. The
individual rate constants are shown in Scheme 1. Signal
response factors for the ﬂuorescence data were calculated
for each concentration of NAD+ to account for inner ﬁlter
effects by normalizing the linear steady-state regions with
the absorbance data. The rate constants for the association
of NAD+ to E·IMP (Scheme S1, k5, k6), hydride transfer
(k7, k8), and NADH release (k9) are well constrained. As
noted above, the release of XMP is fast (g200 s-1); the
Table 1: Steady-State Parameters for CpIMPDH and hIMPDH2
a
CpIMPDH hIMPDH2
parameter NAD+ APAD+ NAD+
kcat (s-1) 2.6 ( 0.1 3.0 ( 0.04 0.39 ( 0.01
c
KM IMP (µM) 13 ( 3n d
d 4 ( 1
c
KM dinucleotide (µM) 140 ( 10 190 ( 96 ( 1
c
Kii dinucleotide (mM)
e 4.9 ( 0.5 na
f 0.59 ( 0.02
c
kcat/KM IMP (M-1 s-1) (2.0 ( 0.5) × 105 nd
d (9.8 ( 1.4) × 104 c
kcat/KM dinucleotide
(M-1 s-1)
(1.9 ( 0.2) × 104 (1.6 ( 0.1) × 104 (6.5 ( 0.5) × 104 c
D2Okcat 2.6 ( 0.1 3.3 ( 0.1 1.8 ( 0.1
a Experimental conditions: 50 mM Tris-HCl, pH 8.0, 100 mM KCl,
and 1 mM DTT at 25 °C.
b APAD+ varied at saturating IMP (500 µM).
c Values from ref 24.
d Not determined.
e Intercept inhibition constant
describing uncompetitive inhibition, nomenclature of Cleland (48).
f Not
applicable.
Table 2: Dissociation Constants for CpIMPDH
ligand Kd (µM)
a
IMP 4.7 ( 0.4
XMP 5.6 ( 0.6
GMP 4.8 ( 0.6
NAD+ 14 ( 1
NADH 2.3 ( 0.2
a Binding reactions were done in 50 mM Tris-HCl, pH 8.0, 100 mM
KCl, and 1 mM DTT at 25 °C.
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ment of the ﬂap were chosen to be arbitrarily fast such that
the value of Kc ) 4( 16). The individual rate constants for
NAD+ binding to E-XMP* (k11, k12) are not well determined,
but the ratio k12/k11 is consistently 200-400 µM. Taking into
account the competition with the ﬂap, this value is in
reasonable agreement with experiment (400 µM × 5 ) 2
mM; Kii ) 4.9 mM, Table 1). The results of the global ﬁts
are summarized in Figure 3, Table S1, and Scheme 1. Using
these values, the calculated value of kcat is 1.8 s-1 (eq 11,
Supporting Information), in agreement with the measured
value of 2.6 s-1. The calculated value of KM NAD+ is 40 µM
(eq 12, Supporting Information), similar to the measured
value of 140 µM.
The Kinetic Mechanism of hIMPDH2. Although hydrolysis
is rate-limiting in the reaction of hIMPDH2 (24, 25), the
pre-steady-state reaction had not been characterized in detail.
When the reaction was monitored by absorbance, the
progress curves display a burst of NADH production and
are well described by a single exponential with a linear steady
state (Figures 4A and S4A). The amplitude of the burst phase
is 0.9 ( 0.1 [NADH]/[E]. The value of kobs ) 14 ( 1s -1 at
saturating substrate concentrations (Table S2), which is 35
times greater than the value of kcat (0.4 s-1).
When the reaction was monitored by ﬂuorescence, the
FIGURE 3: Global ﬁts of the pre-steady-state CpIMPDH reaction of E·IMP with NAD+. (A) Reaction of 2.7 µM enzyme and 500 µM IMP
with NAD+ when monitored by absorbance. (B) Reaction of 1 µM enzyme and 500 µM IMP with NAD+ when monitored by ﬂuorescence.
The progress curves for (a) 0.3, (b) 0.6, (c) 1.25, (d) 2.5, (e) 5, and (f) 10 mM NAD+ have been offset for easier visualization. The global
ﬁts from using Dynaﬁt (22) and the mechanism of Scheme S1 are in red.




kmax (s-1) 41 ( 21 6 ( 1
Kapp (µM) 510 ( 90 290 ( 60
kmax/Kapp (M-1 s-1) 8.0 × 104 5.6 × 104
[NADH]/[E]total 0.43 ( 0.01 nd
b
a Experimental conditions: 1 µM CpIMPDH, 500 µM IMP, 50 mM
Tris-HCl, pH 8.0, 100 mM KCl, and 1 mM DTT at 25 °C. Progress
curves exhibited a single exponential burst phase followed by a linear
steady state and were ﬁt by eq 6. Replots of kobs vs [NAD+] were ﬁt by
eq 8 to derive the above pre-steady-state parameters.
b Not determined.
Scheme 1: Kinetic Alignment of the IMPDH Reaction
a
a The values for TfIMPDH are taken from ref 18. The values for
the CpIMPDH and hIMPDH2 are from the global and local ﬁt analyses
described in the Supplementary Information.
FIGURE 4: Global ﬁts of the pre-steady-state hIMPDH2 reaction of
E·IMP with NAD+. The ﬂuorescence progress curves when 2.8
µM enzyme and 2 mM IMP are combined with (a) 20 µM NAD+,
(b) 40 µM NAD+, (c) 80 µM NAD+, and (d) 200 µM NAD+. The
ﬁts of the data by the mechanism of Scheme S2 are shown in red.
Table 4: Kinetic Parameters for the Pre-Steady-State Reaction of
hIMPDH2 Monitored by Intrinsic Protein Fluorescence
a
parameter lag phase burst phase
kmax (s-1) 23 ( 11 2 ( 1
Kapp (µM) 68 ( 18 6 ( 5
kmax/Kapp (M-1 s-1) 3.4 × 105 1.4 × 105
a Experimental conditions: 4 µM hIMPDH2, 50 mM Tris-HCl, pH
8.0, 100 mM KCl, and 1 mM DTT at 25 °C. Progress curves exhibited
a lag phase followed by a burst and a linear steady state and were ﬁt by
eq 7. Replots of kobs vs [NAD+] were ﬁt by eq 8 to derive the above
pre-steady-state parameters.
Parasite and Host IMPDH Biochemistry, Vol. 47, No. 33, 2008 8693progress curve exhibits three phases, a lag followed by a
burst and a linear steady state, which are well described by
eq 7 (Figures 4 and S4A). Replots of the values of kobs1 and
kobs2 versus [NAD+] are both hyperbolic, with maximum
values of 23 ( 1s -1 and 12 ( 1s -1 for the lag and burst
phases, respectively (Table 4).
These observations suggest that the hydrolysis of E-XMP*
is also rate-limiting in the reaction of hIMPDH2, which
predicts that a solvent deuterium isotope effect will be
observed on kcat; we do observe a solvent deuterium isotope
effect of 1.8 ( 0.1, in contrast to a previous report from
another laboratory (25). This discrepancy may result from
the different reaction conditions (100 mM Tris-HCl, pH 7.7,
and 10 mM KCl at 37 °C whereas our experiments use 50
mM Tris-HCl, pH 8.0, 100 mM KCl, and 1 mM DTT at 25
°C).
Global Fits of the hIMPDH2 Reaction. Values for the
individual rate constants in the kinetic mechanism of
hIMPDH2 were derived as described above and in the
Supporting Information. The individual rate constants derived
from the global and local ﬁt analyses are shown in Scheme
1 and Table S1. The rate constants for the association of
NAD+ to E·IMP (Scheme S2, k5, k6), hydride transfer (k7,
k8), and NADH release (k9) are well constrained. As with
CpIMPDH, the individual rate constants for NAD+ binding
to E-XMP* (k11, k12) are not well determined; the values of
k11 and k12 were set arbitrarily fast such that k12/k11 ) Kii )
590 µM( 24). Importantly, the magnitude of the solvent
isotope effect indicates that hydrolysis is not solely rate-
limiting in the hIMPDH2 reaction. Assuming the intrinsic
isotope effect is 3, as observed in the reaction of CpIMPDH
(as well as in the reaction of serine proteases (26)), then
kHOH ) 1s -1 and k ) 0.7 s-1 for the second rate-limiting
step (27). Both hydride transfer and the release of NADH
are much faster than 0.7 s-1. Unfortunately, hIMPDH2 does
not contain any Trp residues, so the kinetics of ligand binding
cannot be directly measured; nevertheless, given the low
afﬁnity of XMP (Kd ) 140 µM( 28)), the release of XMP is
unlikely to be rate-limiting. Therefore, we propose that the
second rate-limiting step is a conformational change. Since
the open ﬂap conformation is favored in hIMPDH2 (Kc e
0.2) (14), we have provisionally assigned 0.7 s-1 to kclose.
DISCUSSION
We have now characterized the kinetic mechanisms of
TfIMPDH, CpIMPDH, and hIMPDH2; Scheme 1 displays
a “kinetic alignment” of these enzymes. The interchange
between open and closed conformations of the ﬂap is the
most divergent step in these catalytic cycles (Kc in Scheme
1). Since the ﬂap competes with NAD+ for the dinucleo-
tide site, the afﬁnity of NAD+ must be balanced against that
of the ﬂap; otherwise nonproductive complexes such as
E-XMP*·NAD+ will accumulate. When the fraction of
enzyme in the open conformation is taken into account, the
“intrinsic binding afﬁnity” of compounds that bind in the
NAD site can be considerably greater than the observed
binding afﬁnity (Table 5). TfIMPDH dramatically illustrates
this principle: although the observed afﬁnity of NAD+ is the
lowest of the three enzymes, the intrinsic afﬁnity is the
highest. Similar results are observed for the intrinsic afﬁnity
of  -methylene-tiazofurin adenine dinucleotide ( -Me-TAD,
Figure 5). Curiously, the intrinsic afﬁnities of NAD analogues
for CpIMPDH and hIMPDH2 are very similar despite the
divergent structures of these dinucleotide sites. Interestingly,
the intrinsic afﬁnity of  -Me-TAD differentially distributes
across the dinucleotide sites of these three enzymes. The
intrinsic afﬁnity of tiazofurin is similar in TfIMPDH and
CpIMPDH, as expected given that the structures of the
nicotinamide subsites are essentially identical. In contrast,
the nicotinamide subsite of hIMPDH2 contains several
substitutions, and the intrinsic afﬁnity of tiazofurin is
signiﬁcantly lower. The opposite situation is observed at the
adenosine subsite: the intrinsic afﬁnity of ADP is much
higher for TfIMPDH than CpIMPDH. This difference is
likely to arise from interactions with the adenine ring of ADP,
which is sandwiched between Arg241 and Trp269 in
TfIMPDH. These residues are Asn144 and Asn171 in
CpIMPDH. In hIMPDH2, the adenine is sandwiched between
His253 and Phe282, and ADP displays an intrinsic afﬁnity
similar to CpIMPDH.
Remarkably, despite large differences in the dynamics of
the ﬂap, the values of kHOH are identical for CpIMPDH and
TfIMPDH. This observation suggests that the dynamics of
the ﬂap set the stage for the hydrolysis reaction but do not
play an active role in the chemical transformation. The rate
constants for hydride transfer are also similar for CpIMPDH
and TfIMPDH. The residues in the immediate vicinity of
the hypoxanthine and nicotinamide groups are virtually
identical for these two enzymes, so this congruence is also
not surprising. In fact, with the exception of the equilibrium
between open and closed conformations and the binding of
NAD+, the kinetic mechanisms of CpIMPDH and TfIMPDH
are essentially identical. In contrast, both hydride transfer
and hydrolysis are slower in hIMPDH2 than in either of the
Table 5: Intrinsic Binding Energy of Ligands for the Dinucleotide Site
a
NAD+ (mM)  -Me-TAD (µM) Tz (mM) ADP (mM)
enzyme Kc Kii Kintr Ki Kintr Ki Kintr Ki Kintr
TfIMPDH
b 140 6.8 ( 1.8 0.07 2.3 ( 0.4 0.02 50 ( 10 0.3 31 ( 2 0.2
CpIMPDH
c 4 4.9 ( 0.5 0.30 0.6 ( 0.04 0.1 1.5 ( 0.1 0.3 42 ( 68
hIMPDH2
d e0.2 0.59 ( 0.02 0.59 0.06 ( 0.02 0.06 1.3 ( 0.1 1.3 8.8 ( 2.2 8.8
a The intrinsic binding constant for NAD+ is derived from the global ﬁts. The intrinsic binding constants for  -Me-TAD, tiazofurin (Tz), and ADP
are calculated from Kintr ) Ki (1/(1 + Kc)).
b See refs 14 and 23.
c See ref 16.
d See ref 24. The intrinsic binding constant for NAD+ is derived from the
global ﬁts.
FIGURE 5: The structure of  -Me-TAD.
8694 Biochemistry, Vol. 47, No. 33, 2008 Riera et al.parasite enzymes. The equilibrium between the E·IMP·
NAD+ and E-XMP*·NADH complexes also has changed,
which indicates that the transition state for this reaction has
also changed. Several substitutions can be found at the active
site that may account for this behavior. The most intriguing
of these is the substitution of Glu431 with Gln; we have
proposed that Glu431 is part of a proton relay that activates
water and might also function to activate Cys319 (L.
Hedstrom and W. Yang, unpublished). The substitution of
Glu431 with Gln does decrease the value of kcat as expected
(29).
We are aware of four other enzyme systems where the
detailed kinetic mechanisms have been determined for
orthologues: triose-phosphate isomerase, dihydrofolate re-
ductase, purine nucleoside phosphorylase, and adenosine
deaminase. Product release is rate-limiting in the cases of
dihydrofolate reductase and triose-phosphate isomerase, and
the values of kcat are similar in orthologues (30–33). In
contrast, the values of kcat vary by as much as 2 orders of
magnitude, and the chemical transformations are rate-limiting
in purine nucleoside phosphorylase and adenosine deamin-
ase (34, 35). Here the structures of the transition state change,
as we envision the transition structure must change in
hIMPDH2 versus CpIMPDH and TfIMPDH. Interestingly,
substitutions quite remote from the active site contribute to
these changes (36).
Why does C. parVum utilize a bacterial IMPDH? Interest-
ingly, many eukaryotic pathogens, including Trypanomastids,
Giardia lamblia, Entamoeba histolytica, and Trichomonas
Vaginalis, have remodeled and simpliﬁed their metabolic
pathways while adopting bacterial genes, so this phenomenon
is widespread (37–40). One simple hypothesis is that the
higher values of kcat associated with bacterial IMPDHs
promote greater ﬂux through the guanine nucleotide biosyn-
thetic pathways. Our experiments suggest that this is not the
case: though the rate constants for individual steps in the
reactions of CpIMPDH and hIMPDH2 are often signiﬁcantly
different, the ﬂux through both enzymes will be comparable
in ViVo, assuming that the physiological concentrations of
NAD+ and IMP in the parasite are similar to those of most
organisms ([IMP] ) 20-60 µM( 41); [NAD+] ) 0.3-2m M
(42)). Therefore, it seems unlikely that C. parVum chose the
bacterial enzyme to increase the production of guanine
nucleotides. Instead, a moonlighting function may have
provided the impetus for the switch. Virtually all IMPDHs
contain a subdomain. The subdomain is not required for
enzymatic activity (43–45), and its function is currently under
debate. CpIMPDH lacks the subdomain and, therefore, may
be missing the moonlighting functions of the host enzyme.
Intriguingly, the subdomain has recently been shown to
regulate the distribution of purine nucleotides between the
adenine and guanine nucleotide pools in E. coli (46), and it
seems reasonable to expect this regulation would be different
in C. parVum given its unusual purine salvage pathway. We
have found that the subdomain mediates the association of
IMPDH with single-stranded nucleic acids (47) and may well
have an as yet unappreciated role in RNA metabolism that
would also be different in C. parVum.
The kinetic mechanism derived herein has already proved
invaluable in designing a high throughput screen to identify
selective inhibitors of CpIMPDH (19). We used Scheme 1
to deﬁne assay conditions such that the dinucleotide site was
empty in the predominant enzyme forms, thus selecting for
inhibitors that bind to the most diverged site on the enzyme.
These results demonstrate how a detailed understanding of
enzyme kinetics can be important in drug discovery.
SUPPORTING INFORMATION AVAILABLE
Equilibrium ﬂuorescence binding data as well as local and
global ﬁt analyses of the absorbance and ﬂuorescence
stopped-ﬂow data for CpIMPDH and hIMPDH2. This
material is available free of charge via the Internet at http://
pubs.acs.org.
REFERENCES
1. Jackson, R., Weber, G., and Morris, H. P. (1975) IMP dehydro-
genase, an enzyme linked with proliferation and malignancy. Nature
256, 331–333.
2. Pankiewicz, K. W., Lesiak-Watanabe, K. B., Watanabe, K. A.,
Patterson, S. E., Jayaram, H. N., Yalowitz JA, M. M., Seidman,
M., Majumdar, A., Prehna, G., and Goldstein, B. M. (2002) Novel
mycophenolic adenine bis(phosphonate) analogues as potential
differentiation agents against human leukemia. J. Med. Chem. 45,
703–712.
3. Nair, V., and Shu, Q. (2007) Inosine monophosphate dehydrogenase
as a probe in antiviral drug discovery. AntiViral Chem. Chemother.
18, 245–258.
4. Huang, D. B., Chappell, C., and Okhuysen, P. C. (2004) Cryptospo-
ridiosis in children. Semin. Pediatr. Infect. Dis. 15, 253–259.
5. Berkman, D. S., Lescano, A. G., Gilman, R. H., Lopez, S. L., and
Black, M. M. (2002) Effects of stunting, diarrhoeal disease, and
parasitic infection during infancy on cognition in late childhood:
a follow-up study. Lancet 359, 564–571.
6. Huang, D. B., and White, A. C. (2006) An updated review on
Cryptosporidium and Giardia. Gastroenterol. Clin. North. Am. 35,
291–314, viii.
7. Striepen, B., Pruijssers, A. J., Huang, J., Li, C., Gubbels, M. J.,
Umejiego, N. N., Hedstrom, L., and Kissinger, J. C. (2004) Gene
transfer in the evolution of parasite nucleotide biosynthesis. Proc.
Natl. Acad. Sci. U.S.A. 101, 3154–3159.
8. Abrahamsen, M. S., Templeton, T. J., Enomoto, S., Abrahante,
J. E., Zhu, G., Lancto, C. A., Deng, M., Liu, C., Widmer, G.,
Tzipori, S., Buck, G. A., Xu, P., Bankier, A. T., Dear, P. H.,
Konfortov, B. A., Spriggs, H. F., Iyer, L., Anantharaman, V.,
Aravind, L., and Kapur, V. (2004) Complete genome sequence of
the apicomplexan, Cryptosporidium parVum. Science 304, 441–
445.
9. Xu, P., Widmer, G., Wang, Y., Ozaki, L. S., Alves, J. M., Serrano,
M. G., Puiu, D., Manque, P., Akiyoshi, D., Mackey, A. J., Pearson,
W. R., Dear, P. H., Bankier, A. T., Peterson, D. L., Abrahamsen,
M. S., Kapur, V., Tzipori, S., and Buck, G. A. (2004) The genome
of Cryptosporidium hominis. Nature 431, 1107–1112.
10. Striepen, B., White, M. W., Li, C., Guerini, M. N., Malik, S. B.,
Logsdon, J. M., Jr., Liu, C., and Abrahamsen, M. S. (2002) Genetic
complementation in apicomplexan parasites. Proc. Natl. Acad. Sci.
U.S.A. 99, 6304–6309.
11. Huang, J., Mullapudi, N., Lancto, C. A., Scott, M., Abrahamsen,
M. S., and Kissinger, J. C. (2004) Phylogenomic evidence supports
past endosymbiosis, intracellular and horizontal gene transfer in
Cryptosporidium parVum. Genome Biol. 5, R88.
12. Gherardi, A., and Sarciron, M. E. (2007) Molecules targeting the
purine salvage pathway in Apicomplexan parasites. Trends Para-
sitol. 23, 384–389.
13. Hedstrom, L., and Gan, L. (2006) IMP dehydrogenase: structural
schizophrenia and an unusual base. Curr. Opin. Chem. Biol. 10,
520–525.
14. Digits, J. A., and Hedstrom, L. (2000) Drug selectivity is
determined by coupling across the NAD+ site of IMP dehydroge-
nase. Biochemistry 39, 1771–1777.
15. Gan, L., Seyedsayamdost, M. R., Shuto, S., Matsuda, A., Petsko,
G. A., and Hedstrom, L. (2003) The immunosuppressive agent
mizoribine monophosphate forms a transition state analog complex
with IMP dehydrogenase. Biochemistry 42, 857–863.
16. Umejiego, N. N., Li, C., Riera, T., Hedstrom, L., and Striepen, B.
(2004) Cryptosporidium parVum IMP dehydrogenase: Identiﬁcation
Parasite and Host IMPDH Biochemistry, Vol. 47, No. 33, 2008 8695of functional, structural and dynamic properties that can be
exploited for drug design. J. Biol. Chem. 279, 40320–40327.
17. Kohler, G. A., Gong, X., Bentink, S., Theiss, S., Pagani, G. M.,
Agabian, N., and Hedstrom, L. (2005) The functional basis of
mycophenolic acid resistance in Candida albicans IMP dehydro-
genase. J. Biol. Chem. 280, 11295–11302.
18. Guille ´n Schlippe, Y. V., Riera, T. V., Seyedsayamdost, M. R., and
Hedstrom, L. (2004) Substitution of the conserved Arg-Tyr dyad
selectively disrupts the hydrolysis phase of the IMP dehydrogenase
reaction. Biochemistry 43, 4511–4521.
19. Umejiego, N. N., Gollapalli, D., Sharling, L., Volftsun, A., Lu, J.,
Benjamin, N. N., Stroupe, A. H., Riera, T. V., Striepen, B., and
Hedstrom, L. (2008) Targeting a prokaryotic protein in a eukaryotic
pathogen: identiﬁcation of lead compounds against cryptosporidi-
osis. Chem. Biol. 15, 70–77.
20. Wang, W., Papov, V. V., Minakawa, N., Matsuda, A., Biemann,
K., and Hedstrom, L. (1996) Inactivation of inosine 5′-monophos-
phate dehydrogenase by the antiviral agent 5-ethynyl-1- -D-
ribofuranosylimidazole-4-carboxamide 5′-monophosphate. Bio-
chemistry 35, 95–101.
21. Lakowicz, J. R. (1999) Principles of Fluorescence Spectroscopy,
2nd ed., Kluwer Academic/Plenum Publishers, New York.
22. Kuzmic, P. (1996) Program DYNAFIT for the analysis of enzyme
kinetic data: application to HIV proteinase. Anal. Biochem. 237,
260–273.
23. Digits, J. A., and Hedstrom, L. (1999) Kinetic mechanism of
Tritrichomonas foetus inosine-5′-monophosphate dehydrogenase.
Biochemistry 38, 2295–2306.
24. Wang, W., and Hedstrom, L. (1997) The kinetic mechanism of
human inosine 5′-monophosphate type II: random addition of
substrates, ordered release of products. Biochemistry 36, 8479–
8483.
25. Xiang, B., and Markham, G. D. (1997) Probing the mechanism of
inosine monophosphate dehydrogenase with kinetic isotope effects
and NMR determination of the hydride transfer stereospeciﬁcity.
Arch. Biochem. Biophys. 348, 378–382.
26. Hedstrom, L. (2002) Serine protease mechanism and speciﬁcity.
Chem. ReV. 102, 4501–4524.
27. Northrop, D. B. (1975) Steady-state analysis of kinetic isotope
effects in enzymic reactions. Biochemistry 14, 2644–2651.
28. Xiang, B., and Markham, G. D. (1996) The conformation of
inosine-5′-monphosphate (IMP) bound to IMP dehydrogenase
determined by transferred nuclear overhauser effect spectroscopy.
J. Biol. Chem. 271, 27531–27535.
29. Digits, J. A., and Hedstrom, L. (1999) Species-speciﬁc inhibition
of inosine 5′-monophosphate dehydrogenase by mycophenolic acid.
Biochemistry 38, 15388–15397.
30. Fierke, C. A., Johnson, K. A., and Benkovic, S. J. (1987)
Construction and evaluation of the kinetic scheme associated with
dihydrofolate reductase from Escherichia coli. Biochemistry 26,
4085–4092.
31. Andrews, J., Fierke, C. A., Birdsall, B., Ostler, G., Feeney, J.,
Roberts, G. C., and Benkovic, S. J. (1989) A kinetic study of wild-
type and mutant dihydrofolate reductases from Lactobacillus casei.
Biochemistry 28, 5743–5750.
32. Thillet, J., Adams, J. A., and Benkovic, S. J. (1990) The kinetic
mechanism of wild-type and mutant mouse dihydrofolate reduc-
tases. Biochemistry 29, 5195–5202.
33. Nickbarg, E. B., and Knowles, J. R. (1988) Triosephosphate
isomerase: energetics of the reaction catalyzed by the yeast enzyme
expressed in Escherichia coli. Biochemistry 27, 5939–5947.
34. Luo, M., Li, L., and Schramm, V. L. (2008) Remote mutations
alter transition-state structure of human purine nucleoside phos-
phorylase. Biochemistry 47, 2565–2576.
35. Luo, M., Singh, V., Taylor, E. A., and Schramm, V. L. (2007)
Transition-state variation in human, bovine, and Plasmodium
falciparum adenosine deaminases. J. Am. Chem. Soc. 129, 8008–
8017.
36. Saen-Oon, S., Ghanem, M., Schramm, V. L., and Schwartz, S. D.
(2008) Remote mutations and active site dynamics correlate with
catalytic properties of purine nucleoside phosphorylase. Biophys.
J. 94, 4078–4088.
37. Loftus, B., Anderson, I., Davies, R., Alsmark, U. C., Samuelson,
J., Amedeo, P., Roncaglia, P., Berriman, M., Hirt, R. P., Mann,
B. J., Nozaki, T., Suh, B., Pop, M., Duchene, M., Ackers, J.,
Tannich, E., Leippe, M., Hofer, M., Bruchhaus, I., Willhoeft, U.,
Bhattacharya, A., Chillingworth, T., Churcher, C., Hance, Z.,
Harris, B., Harris, D., Jagels, K., Moule, S., Mungall, K., Ormond,
D., Squares, R., Whitehead, S., Quail, M. A., Rabbinowitsch, E.,
Norbertczak, H., Price, C., Wang, Z., Guillen, N., Gilchrist, C.,
Stroup, S. E., Bhattacharya, S., Lohia, A., Foster, P. G., Sicheritz-
Ponten, T., Weber, C., Singh, U., Mukherjee, C., El-Sayed, N. M.,
Petri, W. A., Jr., Clark, C. G., Embley, T. M., Barrell, B., Fraser,
C. M., and Hall, N. (2005) The genome of the protist parasite
Entamoeba histolytica. Nature 433, 865–868.
38. Morrison, H. G., McArthur, A. G., Gillin, F. D., Aley, S. B., Adam,
R. D., Olsen, G. J., Best, A. A., Cande, W. Z., Chen, F., Cipriano,
M. J., Davids, B. J., Dawson, S. C., Elmendorf, H. G., Hehl, A. B.,
Holder, M. E., Huse, S. M., Kim, U. U., Lasek-Nesselquist, E.,
Manning, G., Nigam, A., Nixon, J. E., Palm, D., Passamaneck,
N. E., Prabhu, A., Reich, C. I., Reiner, D. S., Samuelson, J., Svard,
S. G., and Sogin, M. L. (2007) Genomic minimalism in the early
diverging intestinal parasite Giardia lamblia. Science 317, 1921–
1926.
39. Opperdoes, F. R., and Michels, P. A. (2007) Horizontal gene
transfer in trypanosomatids. Trends Parasitol. 23, 470–476.
40. Carlton, J. M., Hirt, R. P., Silva, J. C., Delcher, A. L., Schatz, M.,
Zhao, Q., Wortman, J. R., Bidwell, S. L., Alsmark, U. C., Besteiro,
S., Sicheritz-Ponten, T., Noel, C. J., Dacks, J. B., Foster, P. G.,
Simillion, C., Van de Peer, Y., Miranda-Saavedra, D., Barton, G. J.,
Westrop, G. D., Muller, S., Dessi, D., Fiori, P. L., Ren, Q., Paulsen,
I., Zhang, H., Bastida-Corcuera, F. D., Simoes-Barbosa, A., Brown,
M. T., Hayes, R. D., Mukherjee, M., Okumura, C. Y., Schneider,
R., Smith, A. J., Vanacova, S., Villalvazo, M., Haas, B. J., Pertea,
M., Feldblyum, T. V., Utterback, T. R., Shu, C. L., Osoegawa,
K., de Jong, P. J., Hrdy, I., Horvathova, L., Zubacova, Z., Dolezal,
P., Malik, S. B., Logsdon, J. M., Jr., Henze, K., Gupta, A., Wang,
C. C., Dunne, R. L., Upcroft, J. A., Upcroft, P., White, O., Salzberg,
S. L., Tang, P., Chiu, C. H., Lee, Y. S., Embley, T. M., Coombs,
G. H., Mottram, J. C., Tachezy, J., Fraser-Liggett, C. M., and
Johnson, P. J. (2007) Draft genome sequence of the sexually
transmitted pathogen Trichomonas Vaginalis. Science 315, 207–
212.
41. Traut, T. W. (1994) Physiological concentrations of purines and
pyrimidines. Mol. Cell. Biochem. 140, 1–22.
42. Belenky, P., Bogan, K. L., and Brenner, C. (2007) NAD+
metabolism in health and disease. Trends Biochem. Sci. 32, 12–
19.
43. Zhou, X., Cahoon, M., Rosa, P., and Hedstrom, L. (1997)
Expression, puriﬁcation and charcterization of inosine-5′-mono-
phosphate dehydrogenase from Borrelia burgdorferi. J. Biol. Chem.
272, 21977–21981.
44. Nimmesgern, E., Black, J., Futer, O., Fulghum, J. R., Chambers,
S. P., Brummel, C. L., Raybuck, S. A., and Sintchak, M. D. (1999)
Biochemical analysis of the modular enzyme inosine monophos-
phate dehydrogenase. Protein Expression Purif. 17, 282–289.
45. Gan, L., Petsko, G. A., and Hedstrom, L. (2002) Crystal structure
of a ternary complex of Tritrichomonas foetus inosine 5′-mono-
phosphate dehydrogenase: NAD+ orients the active site loop for
catalysis. Biochemistry 41, 13309–13317.
46. Pimkin, M., and Markham, G. D. (2008) The CBS subdomain of
inosine 5′-monophosphate dehydrogenase regulates purine nucle-
otide turnover. Mol. Microbiol. 69, 342–259.
47. McLean, J. E., Hamaguchi, N., Belenky, P., Mortimer, S. E.,
Stanton, M., and Hedstrom, L. (2004) Inosine 5′-monophosphate
dehydrogenase binds nucleic acids in vitro and in vivo. Biochem.
J. 379, 243–251.
48. Cleland, W. W. (1963) The kinetics of enzyme-catalyzed reactions
with two or more substrates or products. I. Nomenclature and rate
equations. Biochim. Biophys. Acta 67, 104–137.
49. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S.,
Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004) UCSF
Chimerasa visualization system for exploratory research and
analysis. J. Comput. Chem. 25, 1605–1612.
BI800674A
8696 Biochemistry, Vol. 47, No. 33, 2008 Riera et al.